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Abstract 
MUTYH is involved in DNA damage repair. Bi-allelic MUTYH mutations predispose to polyposis and 
gastrointestinal malignancies, distinct genetically from autosomal dominant familial adenomatous 
polyposis coli. Two common European MUTYH mutations account for 90% of MUTYH-associated 
polyposis (MAP). We aimed to examine the incidence of MAP in Ireland. A retrospective cohort study 
was undertaken. Patients undergoing MUTYH testing from 2003-2016 were identified by searching 
electronic databases using terms "MUTYH" and "MYH". Phenotypic and genotypic details were 
obtained by chart review. Bi-allelic mutations were confirmed in 26 individuals (17 families), of 
whom 16 (62%) developed colorectal malignancies, and 22(85%) polyposis. Eleven families had bi-
allelic status for one/both common European mutations. Regional variation was noted, with over-
representation of bi-allelic mutation carriers in the South-west of Ireland. MAP is under-diagnosed 
in Ireland. Increased awareness is required to facilitate appropriate identification and surveillance of 
bi-allelic mutation carriers for colorectal pathology.  
Introduction 
To date, numerous colorectal cancer and polyposis syndromes have been described, 
including familial adenomatous polyposis (FAP), Peutz-Jeghers syndrome, Juvenile polyposis 
syndrome and hereditary mixed polyposis. Polyposis syndromes confer a risk of malignancy 
as well as polyps, given that, irrespective of the genetic aetiology, changes in any individual 
polyp along the adenoma-carcinoma pathway may lead to the development of colorectal 
cancer, a risk that increases with increasing polyp burden. Lynch syndrome (Hereditary Non-
Polyposis Colorectal Cancer syndrome) predisposes to colorectal and other cancers in the 
absence of preceding polyposis1. 
MUTYH-associated polyposis (MAP) was the first recessively-inherited polyposis syndrome 
to be described2. The phenotype of MAP is similar to that of attenuated familial 
adenomatous polyposis (FAP), with colonic polyp burden ranging from tens to a few 
hundred, developing at a mean age of fifty. MAP is also associated with other 
gastrointestinal polyps, duodenal cancer3 and extra-intestinal malignancies, including ovary 
and bladder. There is also some conflicting evidence of an association with breast and 
endometrial cancers 3-5. 
To date, 306 unique DNA variants in MUTYH have been detected in 8514 individuals 
worldwide6. In Northern European populations however,  bi-allelic combinations of two 
common missense variants,   c.536A>G (p.Tyr179Cys) in exon 7 
and c.1187G>A(p.Gly396Asp) in exon 13, are reported in 70% of patients with MAP7, and at 
least one of these two mutations are detected in 90% cases. The combined carrier 
frequency of the two common mutations in unaffected controls of European origin ranges 
from 1 in 80 to 1 in 5007. Large ethnic variations in carrier frequency exist, however, and the 
two common missense mutations have not been reported with the same frequency in 
Asian 8, 9 or Jewish populations 10, suggesting a founder effect 7. 
The majority of germline testing of MUTYH for patients in the Republic of Ireland is co-
ordinated through a single molecular laboratory based in the Department of Clinical 
Genetics at Our Lady’s Children’s Hospital Crumlin. The aims of this study were to examine 
the incidence and impact of MYH mutations in Irish patients referred for genetic 
counselling/testing, to identify a genotype-phenotype association, and to investigate the 
clinical outcome of mono-allelic MUTYH mutation carriers. 
Methods 
A retrospective cohort study was undertaken. The cohort under investigation included 
mono-allelic and bi-allelic MUTYH carriers identified on testing performed via the molecular 
laboratory in Our Lady’s Children’s Hospital Crumlin. Probands included Irish patients tested 
in Ireland; patients of non-Irish origin tested in Ireland, and Irish patients tested abroad 
where family members had attended for cascade testing. Patients referred 
for MUTYH testing between 2003 and February 2016 were identified by searching 
departmental electronic patient databases (iGene and Crumbase) using keywords “MUTYH” 
and “MYH”. Mutation testing was performed by real-time assay for two common European 
mutations, with full sequencing of the gene in the case of patients with convincing MAP 
phenotype with only mono-allelic or no mutation detected by rtPCR. Six probands with 
severe phenotype also underwent sequencing of the APC gene. Details regarding phenotype 
and genotype were obtained by chart review. 
Results 
MUTYH analysis was performed in 120 patients from 61 families, including diagnostic testing 
in 58 probands. Seventeen unrelated probands were found to carry bi-
allelic MUTYH mutations, including one patient of Portuguese ethnicity. One proband with a 
convincing phenotype underwent diagnostic testing for the two common European 
mutations only. One mutation has been identified, and full MUTYH sequencing is underway 
to identify the second mutation. During cascade screening, a further nine bi-allelic mutation 
carriers and twenty-nine mono-allelic mutation carriers were identified (Table 1). 
  
  
The mutations most commonly reported in our cohort were the two common European 
mutations, with c.536A>G homozygosity reported in four families; c.1187G>A homozygosity 
in three families; and compound heterozygosity of the two mutations in three families. Five 
families had compound heterozygote genotypes including at least one of the two common 
European mutations.  All six bi-allelic c.536A>G homozygous mutation carriers were affected 
by cancer on a background of polyposis, at mean age 49 years (±13.2). Of six c.1187G>A 
homozygous mutation carriers, three siblings developed colon cancer at mean age 47.5 
years (±6.4).  The phenotypes of all bi-allelic mutation carriers are outlined in table 2. There 
were no cases of duodenal, ovarian, bladder, breast or endometrial cancers among bi- allelic 
mutation carriers in this series. 
 Two patients were found to carry variants of unknown significance after undergoing full 
MUTYH sequencing. One of these patients had ~12 polyps at age 49, and was found to carry 
two variants of uncertain significance, c.-2C>G (p.Ala2Pro) and c.1256C>A (p.Ala419Asp). 
Another patient presented with polyposis at age 79, and was found to carry a single MUTYH 
variant c.312C>T (p.Tyr104=). 
 Diagnostic testing of patients for cancer predisposition using next-generation panels 
including MUTYH identified a number of mono-allelic mutation carriers. One patient 
underwent such testing following diagnosis of adenocarcinoma of the pancreas on a 
background of strong familial history of colorectal, ovarian, liver and pancreatic cancer. In 
this family, the MUTYH mutation was not shown to segregate with disease. Another index 
patient underwent panel testing for polyposis predisposition, and was found to carry a 
single paternally inherited MUTYH mutation (c.1187G>A) as well as a pathogenic de novo 
mutation in the APC gene (c.568delG, p.Glu190Asnfs*15).  This patient had a classical 
phenotype of Familial Adenomatous Polyposis, with 250 adenomatous polyps on 
colonoscopy aged 21 years. There was no family history of polyposis or cancer in this 
instance. Several obligate carriers of MUTYH mutations were noted to have a previous 
history of malignancy, including of the stomach, oesophagus and endometrium as well as 
colorectal disease (Table 3). However the majority of obligate carriers did not report a 
history of malignancy or polyposis.   Among mono-allelic MUTYH mutation carriers picked 
up on cascade testing (n=29), the majority had not undergone colonoscopy. Of those that 
did (n=8), seven had normal tests, and one had a solitary colonic polyp.  
 A local geographical difference in incidence of MUTYH-associated polyposis was noted, with 
marked predominance in the South of the country (table 4). Six of sixteen apparently 
unrelated families originated from Co. Cork, a further three from neighbouring Co. Kerry, 
and one from Co. Waterford. Another family originated in Co. Limerick, and two from Co. 
Galway. A disproportionately small number of families (n=3) originated from Co. Dublin, 
given the distribution of the population in Ireland. One family was of Portuguese origin and 
now live in Dublin. The rates of colorectal cancer nationally have also shown a regional 
variation, with observed incidence of colorectal cancers. Invasive cancers in Co. Cork have 
been higher than that expected in both periods between 1994-2003 and 2004-2012 11. 
Discussion 
Cancer arises as a result of sequential acquisition of genetic mutations, caused by 
exogenous or endogenous mutagens. There are intrinsic DNA repair mechanisms to repair 
such mutations, and MYH polyposis is a genetic disorder of one such DNA repair 
mechanism. DNA repair mechanisms have generated particular interest of late, given that 
last year’s Nobel Prize in Chemistry was jointly awarded to three renowned scientists in this 
field12. 
In our series, c.536A>G homozygotes were found to develop a more severe phenotype than 
c.1187G>A homozygotes or c.536A>G/c.1187G>A compound heterozygotes. All c.536A>G 
homozygotes developed polyposis and subsequent colorectal malignancy. Comparatively, 
the cancers occurring in c.1187G>A homozygotes were limited to a single sibship (n=3), with 
one further c.1187G>A homozygote in the same family developing only a single benign 
polyp. One of three c.1187G>A/c.536A>G compound heterozygote developed early onset 
colon cancer. This finding has been previously documented7,13  and is attributed to different 
effects of these mutations at a functional level.  The c.1187G>A mutation acts to structurally 
modify a C-terminal turn, resulting in partially deficient DNA glycosylase activity, and 
appears to be less catalytically compromised than the c.536A>G mutation in the N-terminal 
catalytic base excision domain which results in dramatically reduced glycosylase activity and 
reduced base-flipping ability2,7,14. The c.536A>G mutation is also more often associated with 
larger accumulation of endogenous DNA damage 14.  Interestingly, in our series, four 
patients developed malignancy without prior polyposis, of whom three were c.1187G>A 
homozygotes, and one c.1187G>A/c.933+3A>C compound heterozygote. This is in-keeping 
with previous literature, highlighting a risk of colorectal cancer in MAP even in the absence 
of polyposis 15. 
Other mutations identified in our cohort included a Portuguese founder mutation, 
c.1227_1228dupGG (p.Gly410Glyfs) 16 in a Portuguese patient; c.1435G>T (p.Val493Phe), 
previously reported in a French cohort 17, and c.1147delC (p.Ala385Profs*23), common in 
patients of Northern European origin 7; and c.933+3A>C (p.Gly264Trpfs*7), which has been 
reported as an Italian founder mutation, and with lesser frequency in other Western 
European populations 17, 18. A novel c.337T>C (p.Trp113Arg) variant was detected in two 
compound heterozygotes with convincing MAP phenotypes. In silico analyses suggest high 
likelihood of pathogenicity. 
A single patient in our cohort with a c.933+3A>C homozygous genotype  had the most 
severe polyp burden in the cohort, as well as early onset malignancy, This mutation alters 
the sequence of the donor splice site in intron 10, resulting in skipping of exon 10 18. In 
lymphoblastoid cell lines (LCLs), this splice-site mutation was found to encode a non-
functional protein (G264WfsX7). The amount of normal protein produced by LCLs with 
c.933+3A>C depends on the second mutation, and ranges between 1-100% of that produced 
by wild type LCLs. In c.933+3A>C/c.933+3A>C homozygous LCLs some primary transcripts 
were noted to avoid abnormal splicing, resulting in formation of some full-length, wild-type 
protein 19.  Homozygous c.933+3A>C/c.933+3A>C cell lines were noted to produce ~10% 
normal protein 18. Maintenance of some residual MUTYH activity should predict an 
attenuated phenotype in c.933+3A>c/c.933+3A>C homozygotes compared to carriers of 
mutations associated with complete MUTYH inactivation 18. The severe phenotype in the 
patient with this genotype in our cohort is therefore suggestive of a possible concomitant 
genetic or environmental modifier. 
The risk of colorectal cancer in heterozygous carriers of a single MUTYH mutation is unclear. 
A large scale meta-analysis suggests that there may be a marginally risk associated with 
mono-allelic c.536A>G mutations, but not for c.1187G>A, but this effect did not retain 
statistical significance after Bonferroni correction for multiple analyses 13, and was not felt to 
be clinically actionable. In this series, no mono-allelic carriers picked up on cascade testing 
had a history of malignancy or polyposis, and colonoscopic screening undertaken by some of 
these patients (n=8) revealed a solitary polyp in only one individual. Considering only 
parents of bi-allelic carriers, this series includes at least 34 obligate carriers, and most did 
not have a positive history of malignant disease, although cancers were reported in 6 
individuals. 
Given the phenotype associated with bi-allelic MUTYH mutations, it is strongly 
recommended that bi-allelic mutation carriers be appropriately identified to facilitate 
surveillance for colorectal disease. For full siblings of patients with MAP, assuming the 
parents are obligate carriers, the risk that they are also affected is 1 in 4 (25%), while the 
risk that they are a mono-allelic carrier is 2/3 (66%). The risk of transmission of a single 
mutation in MUTYH to the child of a bi-allelic mutation carrier is 100%, but the risk of the 
child being affected by MAP (i.e. inheriting second mutation from the other parent) depends 
on the carrier status of the other parent, who has a general population risk (~1%).  Cascade 
testing in our centre is offered to sibs, partners and/or offspring of bi-allelic mutation 
carriers. Current screening guidelines for mono- and bi-allelic MUTYH mutation carriers are 
based on recommendations following from a meeting of European experts in Mallorca in 
2007 20. Currently, colorectal surveillance of bi-allelic MUTYH mutation carriers follows that 
of patients with APC-related familial adenomatous polyposis, with colonoscopy 
recommended to start between 18-20 years, at 2-yearly intervals. Screening of mono-
allelic MUTYH-carriers is not recommended outside of national screening programs 20. 
The prevalence of bi-allelic MUTYH mutations is expected to be between 1/40,000-
1/20,00021. Given a population of ~4.8 million in Ireland, we can estimate that there are 120-
240 bi-allelic mutation carriers in the country. A minority of these will be children or young 
adults who have not yet developed symptoms of the condition.  It is clear however, 
that MUTYH-associated polyposis is under-recognised and under-diagnosed in 
Ireland. MUTYH-gene analysis should therefore be routinely considered in all patients with 
polyposis if APC-gene analysis is negative or family history suggests recessive inheritance. 
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